Categories: Technology

PROACTIS SA – Press Release (nomination C. Carter and P. Shepherd) 19.12.2025

Press Release

Evolution of PROACTIS SA Governance

PARIS, France – (19 December 2025) — Under the terms of the Board of Directors of the company PROACTIS SA (ISIN code: FR0004052561) held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning.

Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in our next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan.

During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning.

Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution.

Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31st, 2026.

As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows:

Member Functions Mandate expiry date
Andrew REARDON Chairman of the Board of Directors
Chief Executive Officer
Annual General Meeting to approve the financial statements for the year ending January 31, 2028
Charlotte CARTER Director Annual General Meeting to approve the financial statements for the year ending January 31, 2030
Peter SHEPHERD Director Annual General Meeting to approve the financial statements for the year ending January 31, 2028
Maria LARSEN Director Annual General Meeting to approve the financial statements for the year ending January 31, 2028

* * * *

Contacts
Tel: +33 (0)1 53 25 55 00
E-mail: investorContact@proactis.com

* * * *

GlobeNews Wire

Recent Posts

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company…

1 hour ago

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more…

1 hour ago

Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism…

1 hour ago

Microvast Schedules Fourth Quarter Earnings Call

March 13, 2026 15:00 ET  | Source: Microvast Holdings, Inc. STAFFORD, Texas, March 13, 2026…

3 hours ago

Cloud Signature Consortium Announces Trust Without Borders Summit 2026 in Bogot

Brussels, March 13, 2026 (GLOBE NEWSWIRE) -- The Cloud Signature Consortium (CSC) announced the full…

3 hours ago

Shekhar Natarajan Introduces Trust Ecology, a New AI Paradigm Built on Angelic Intelligence

SAN FRANCISCO, March 13, 2026 (GLOBE NEWSWIRE) -- In response to the growing complexity of…

3 hours ago